Abpro Bioresearch

Whether you are assessing small molecule drug candidate efficacy in a human xenograft tumor mouse model, or evaluation of immune-based therapies in a syngeneic mouse tumor model, Abpro BIoresearch provides you with the expertise in a wide variety of models and dosing routes and regimens to suit your needs. Efficacy as measured by tumor growth kinetics can be combined with pharmacokinetics, clinical pathology, histopathology and local/systemic immune function profiling in the following models:

• Xenograft tumor models
  
• Syngeneic mouse tumor models
  
• PDX models
  
• Custom models upon request
  

Abpro offers a full range of in vivo non-GLP toxicology services in both mice and rats providing early assessment of drug candidate toxicity allowing for a more informed drug discovery direction and more confident decision-making. Examples of our toxicology study capabilities include:

• Toxicokinetics
  
• Maximum tolerated dose estimation (fixed or up and down dosing schedule)
  
• Acute toxicity (up to 14 days)
  
• Single or repeated dose
  
• NOEL/NOAEL
  

with noncompartmental and compartmental analysis

Abpro offers in vivo preclinical pharmacology services in both mouse and rat using a full range of dosing administration routes and regimens for both small molecules and biologics. Tissue and body fluid samples can either be shipped to the sponsor or undergo bioanalysis at Abpro.

Choosing the most appropriate model for your metabolic disease research and drug development projects is crucial for proper efficacy assessment of therapeutic interventions. At Abpro, we can work with you to choose the most appropriate model for your disease area from a wide array of genetic or (diet or drug) induced disease models. Examples include:

• Type I and II diabetes models
  
• Nutritional and genetic obesity models
  
• Dyslipidemia
  
• Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)
  

With the wide range of rodent autoimmune and inflammatory models of human disease it can be confusing to decide which model is best for your particular drug development and research needs. Our immunology scientists have the knowledge and experience to help you design the most appropriate studies for your goals. We can provide you a comprehensive qualitative and quantitative assessment of immune cell populations and functional readouts. Examples of our disease models include:

• Systemic Lupus Erythematosus (SLE)
  
• Multiple Sclerosis
  
• Type 1 diabetes
  
• Psoriasis
  
• Inflammatory Bowel Disease
  

Abpro has a highly talented team of immunoassay scientists with extensive assay development experience. Our team has delivered high quality, functional monoclonal antibodies and corresponding assays to traditionally difficult targets (e.g., GPCRs, high homology proteins, idiotypes). Our expertise includes, but is not limited to: sandwich ELISAs for diagnostic kit development, competition, neutralizing, and blocking assays for drug screening and development.

In addition to assay development, we also have high throughput screening capabilities. Our platform leverages state-of-the-art automation to process and screen a huge volume of samples accurately and efficiently. Our screening capabilities include:

• ELISA
  
• Affinity Ranking (ForteBio Octet™)
  
• Western Blots
  
• Flow Cytometry
  
• Immunoprecipitation
  
• Dot Blot
  

Assay development and high throughput screening can be included as part of a custom antibody development project or offered as an independent service.

Drug Discovery & Development Services

Oncology Animal Models Services - Xenograft, syngeneic, PDX
Also offer a wide array of genetic or induced disease models such as Type I and II diabetes models, inflammatory bowel disease

In vitro Toxicity Testing Services

Oncology Animal Models Services

Rodent Models Services